NO972707L - Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon - Google Patents
Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjonInfo
- Publication number
- NO972707L NO972707L NO972707A NO972707A NO972707L NO 972707 L NO972707 L NO 972707L NO 972707 A NO972707 A NO 972707A NO 972707 A NO972707 A NO 972707A NO 972707 L NO972707 L NO 972707L
- Authority
- NO
- Norway
- Prior art keywords
- receptor
- opioid
- modulating
- compound
- receptor function
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000556 agonist Substances 0.000 abstract 2
- 239000001961 anticonvulsive agent Substances 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000000018 receptor agonist Substances 0.000 abstract 2
- 229940044601 receptor agonist Drugs 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000001773 anti-convulsant effect Effects 0.000 abstract 1
- 230000003556 anti-epileptic effect Effects 0.000 abstract 1
- 229960003965 antiepileptics Drugs 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000000949 anxiolytic effect Effects 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 238000007423 screening assay Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9486—Analgesics, e.g. opiates, aspirine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Foreliggende oppfinnelse vedrører en metode for å påvise en terapeutisk nyttig forbindelse, omfattende å teste en LC132-receptoragonist i et utsorterings- assay for psykiatriske og/eller neurologiske lidel- ser. Nærmere bestemt baserer seg utsorteringsmetoden på å bringe en LC132-receptor i berøring med en forbindelse som man tror at er en LC132-receptor- agonist etterfulgt av påvisningen av bindingen og/eller agonistaktiviteten av forbindelsen, og deretter å teste et middel som har LC132-agonistaktivitet, i et antiepileptisk, antikonvulsivt eller anxiolytisk utsorteringsassay.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96109462 | 1996-06-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO972707D0 NO972707D0 (no) | 1997-06-12 |
| NO972707L true NO972707L (no) | 1997-12-15 |
Family
ID=8222893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO972707A NO972707L (no) | 1996-06-13 | 1997-06-12 | Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US6326156B1 (no) |
| JP (1) | JP3212537B2 (no) |
| KR (1) | KR100247670B1 (no) |
| CN (1) | CN1184254A (no) |
| AR (1) | AR007548A1 (no) |
| AU (1) | AU719519B2 (no) |
| BR (1) | BR9703546A (no) |
| CA (1) | CA2206192A1 (no) |
| CZ (1) | CZ179597A3 (no) |
| HU (1) | HUP9701032A3 (no) |
| IL (1) | IL121017A0 (no) |
| MX (1) | MX9704352A (no) |
| NO (1) | NO972707L (no) |
| NZ (1) | NZ328033A (no) |
| PL (1) | PL320527A1 (no) |
| TR (1) | TR199700482A2 (no) |
| ZA (1) | ZA975077B (no) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003279877B2 (en) * | 2002-10-07 | 2010-05-20 | The Regents Of The University Of California | Modulation of anxiety through blockade of anandamide hydrolysis |
| WO2008030752A2 (en) * | 2006-09-07 | 2008-03-13 | N.V. Organon | Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo |
| JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| CA2674359A1 (en) * | 2006-11-20 | 2008-05-29 | N.V. Organon | Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
| JP5637982B2 (ja) | 2008-04-09 | 2014-12-10 | インフィニティー ファーマシューティカルズ, インコーポレイテッド | 脂肪酸アミド加水分解酵素の阻害剤 |
| US8541581B2 (en) | 2009-04-07 | 2013-09-24 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| AU2010234445A1 (en) | 2009-04-07 | 2011-11-03 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| US8927551B2 (en) * | 2009-05-18 | 2015-01-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| US9149465B2 (en) * | 2009-05-18 | 2015-10-06 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| US8765735B2 (en) * | 2009-05-18 | 2014-07-01 | Infinity Pharmaceuticals, Inc. | Isoxazolines as inhibitors of fatty acid amide hydrolase |
| WO2011097233A1 (en) | 2010-02-03 | 2011-08-11 | Infinity Pharmaceuticals, Inc. | Fatty acid amide hydrolase inhibitors |
| RU2583435C2 (ru) | 2010-07-28 | 2016-05-10 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Ингибиторы faah периферически-ограниченного действия |
| KR102079404B1 (ko) | 2011-08-19 | 2020-02-19 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 메타-치환된 비페닐 말초 제한형 faah 억제제 |
| WO2013049332A1 (en) | 2011-09-29 | 2013-04-04 | Infinity Pharmaceuticals, Inc. | Inhibitors of monoacylglycerol lipase and methods of their use |
| EP3988540A1 (en) | 2014-04-07 | 2022-04-27 | The Regents of the University of California | Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments |
| CN114796446B (zh) * | 2021-01-22 | 2024-08-30 | 宁夏杞肽科技有限公司 | 孤啡肽治疗氯胺酮成瘾的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5316759A (en) * | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
| DE3718317A1 (de) | 1986-12-10 | 1988-06-16 | Bayer Ag | Substituierte basische 2-aminotetraline |
| EP0612845A3 (en) | 1993-02-26 | 1994-09-21 | American Cyanamid Co | Purified opioid receptor. |
| US6096513A (en) | 1993-05-20 | 2000-08-01 | Arch Development Corporation | Polynucleotides encoding KAPPA opiod receptors |
| US5658783A (en) * | 1993-11-08 | 1997-08-19 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization | Mammalian methadone-specific opioid receptor gene and uses |
| US5476933A (en) * | 1994-11-16 | 1995-12-19 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Azepine synthesis via a diels-alder reaction |
| US5821219A (en) | 1995-08-11 | 1998-10-13 | Oregon Health Sciences University | Opioid antagonists and methods of their use |
| JP4191796B2 (ja) | 1995-08-15 | 2008-12-03 | ユーロスクリーン・ソシエテ・アノニム | 拮抗剤または作動剤として、ヒトorl1受容体に結合できることが知られていない化合物を回収する方法 |
-
1997
- 1997-05-27 CA CA002206192A patent/CA2206192A1/en not_active Abandoned
- 1997-06-03 US US08/868,355 patent/US6326156B1/en not_active Expired - Fee Related
- 1997-06-06 NZ NZ328033A patent/NZ328033A/en unknown
- 1997-06-06 IL IL12101797A patent/IL121017A0/xx unknown
- 1997-06-09 JP JP15117397A patent/JP3212537B2/ja not_active Expired - Fee Related
- 1997-06-09 TR TR97/00482A patent/TR199700482A2/xx unknown
- 1997-06-09 ZA ZA9705077A patent/ZA975077B/xx unknown
- 1997-06-11 AR ARP970102532A patent/AR007548A1/es unknown
- 1997-06-11 HU HU9701032A patent/HUP9701032A3/hu unknown
- 1997-06-11 CZ CZ971795A patent/CZ179597A3/cs unknown
- 1997-06-12 PL PL97320527A patent/PL320527A1/xx unknown
- 1997-06-12 NO NO972707A patent/NO972707L/no not_active Application Discontinuation
- 1997-06-12 CN CN97113212A patent/CN1184254A/zh active Pending
- 1997-06-12 MX MX9704352A patent/MX9704352A/es unknown
- 1997-06-12 AU AU24853/97A patent/AU719519B2/en not_active Ceased
- 1997-06-12 KR KR1019970024220A patent/KR100247670B1/ko not_active Expired - Fee Related
- 1997-06-13 BR BR9703546A patent/BR9703546A/pt active Search and Examination
-
2001
- 2001-08-14 US US09/929,986 patent/US20020082213A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ZA975077B (en) | 1997-12-15 |
| HU9701032D0 (en) | 1997-07-28 |
| NZ328033A (en) | 1998-11-25 |
| MX9704352A (es) | 1997-12-31 |
| US20020082213A1 (en) | 2002-06-27 |
| TR199700482A2 (xx) | 1998-01-21 |
| AU719519B2 (en) | 2000-05-11 |
| PL320527A1 (en) | 1997-12-22 |
| CA2206192A1 (en) | 1997-12-13 |
| US6326156B1 (en) | 2001-12-04 |
| IL121017A0 (en) | 1997-11-20 |
| JPH1068724A (ja) | 1998-03-10 |
| BR9703546A (pt) | 1998-09-29 |
| KR980003586A (ko) | 1998-03-30 |
| CZ179597A3 (cs) | 1998-03-18 |
| AU2485397A (en) | 1997-12-18 |
| KR100247670B1 (ko) | 2000-06-01 |
| CN1184254A (zh) | 1998-06-10 |
| AR007548A1 (es) | 1999-11-10 |
| HUP9701032A3 (en) | 2000-04-28 |
| NO972707D0 (no) | 1997-06-12 |
| HUP9701032A2 (hu) | 1998-08-28 |
| JP3212537B2 (ja) | 2001-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO972707L (no) | Fremgangsmåte ved modulering av LC132 (opioid-liknende) reseptorfunksjon | |
| AU3538195A (en) | Assays and devices for the detection of extrahepatic biliary atresia | |
| NZ306051A (en) | Testing using electrochemiluminescence | |
| DK0943097T3 (da) | Fremgangsmåde til at påvise IgE | |
| TW347467B (en) | Method and apparatus for testing an electrically conductive substrate | |
| WO2000021987A3 (en) | A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease | |
| ATE351921T1 (de) | Verfahren für fluoreszenzerkennungstest | |
| WO2003069304A3 (en) | Method and apparatus for assay of electrochemical properties | |
| WO2003057029A8 (en) | System and method of assessment of neurological conditions using eeg bispectrum | |
| DE69936453D1 (de) | Für einen g-protein gekoppelten rezeptor, der an der empfindungstransduktion beteiligt ist, kodierende nukleinsäuren | |
| EP1055239B8 (en) | Ultrasensitive surveillance of sensors and processes | |
| BG104275A (en) | Method and device for express analysis of tested parameters in biological samples | |
| CA2033168A1 (en) | Method of Optical Analysis | |
| EA200100899A1 (ru) | ЦИТОЗОЛЬНАЯ ФОСФОЛИПАЗА A2 (cPLA2) И МОДЕЛЬ ЕЕ СТРУКТУРЫ, КРИСТАЛЛИЧЕСКАЯ КОМПОЗИЦИЯ, КОМПЬЮТЕРНАЯ СИСТЕМА, СПОСОБ ИДЕНТИФИКАЦИИ МОЛЕКУЛЫ И МОЛЕКУЛА, СПОСОБ ИДЕНТИФИКАЦИИ СУБСТАНЦИИ (ВАРИАНТЫ), СПОСОБ ИДЕНТИФИКАЦИИ ИНГИБИТОРОВ (ВАРИАНТЫ), АГОНИСТ ИЛИ АНТАГОНИСТ (ВАРИАНТЫ), СУБСТАНЦИЯ (ВАРИАНТЫ) | |
| WO2002000933A3 (en) | Screening assays for identifying modulators of the inflammatory or immune responses | |
| CA2204305A1 (en) | Apparatus and method for determination of urine color | |
| AUPM411294A0 (en) | Evaluation of signal processor performance | |
| MX9606584A (es) | Biosensores sensibles a masas. | |
| MXPA03011898A (es) | Ensayo de seleccion in vitro para ?- secretasa. | |
| ES2195037T3 (es) | Sistema de prueba elisa para detectar substancias que interfieren con el enlace entre ig e y su receptor. | |
| WO1991012339A3 (en) | Allelic association of the human dopamine (d2) receptor gene in compulsive disorders such as alcoholism | |
| EP0813065A3 (en) | Modulation of LC132 (opioid-like) receptor function | |
| FR2783326B1 (fr) | Procede de detection ou de quantification des basophiles et des eosinophiles | |
| WO1998049292A3 (fr) | Polypeptides associes a des recepteurs activateurs et leurs applications biologiques | |
| AU6560096A (en) | Homogeneous gene probe test using a receptor directed against the label |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |